Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Conscientious objection and person-centered care.

Buetow S, Gauld N.

Theor Med Bioeth. 2018 Apr;39(2):143-155. doi: 10.1007/s11017-018-9443-2.

PMID:
30027494
2.

Double-Dosing and Other Dangers with Non-Prescription Medicines: Pharmacists' Views and Experiences.

Gauld N, Sullivan T.

Pharmacy (Basel). 2018 Jul 2;6(3). pii: E59. doi: 10.3390/pharmacy6030059.

3.

Pharmacist supply of sildenafil: pharmacists' experiences and perceptions on training and tools for supply.

Braund R, Ratnayake K, Tong K, Song J, Chai S, Gauld N.

Int J Clin Pharm. 2018 Jun;40(3):650-658. doi: 10.1007/s11096-018-0622-z. Epub 2018 Mar 31.

PMID:
29605946
4.

Antibiotic treatment of women with uncomplicated cystitis before and after allowing pharmacist-supply of trimethoprim.

Gauld NJ, Zeng IS, Ikram RB, Thomas MG, Buetow SA.

Int J Clin Pharm. 2017 Feb;39(1):165-172. doi: 10.1007/s11096-016-0415-1. Epub 2016 Dec 23.

PMID:
28012119
5.

Reasons for use and non-use of the pertussis vaccine during pregnancy: an interview study.

Gauld NJ, Braganza CS, Babalola OO, Huynh TT, Hook SM.

J Prim Health Care. 2016 Dec;8(4):344-350. doi: 10.1071/HC15049.

PMID:
29530159
6.

Pharmacist-only trimethoprim: pharmacist satisfaction on their training and the impact on their practice.

Braund R, Henderson E, McNab E, Sarten R, Wallace E, Gauld N.

Int J Clin Pharm. 2016 Dec;38(6):1357-1361. Epub 2016 Nov 10.

PMID:
27832404
7.

Treatment of uncomplicated cystitis: analysis of prescribing in New Zealand.

Gauld NJ, Zeng IS, Ikram RB, Thomas MG, Buetow SA.

N Z Med J. 2016 Jul 1;129(1437):55-63.

PMID:
27362599
8.

Barriers to positive policy change that aims to increase access to medicines through reclassification: the case of oseltamivir in New Zealand.

Shaw JP, Gauld N, Kelly F.

Int J Pharm Pract. 2016 Feb;24(1):6-12. doi: 10.1111/ijpp.12200. Epub 2015 Jul 7.

PMID:
26154432
9.

Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries.

Gauld N, Bryant L, Emmerton L, Kelly F, Kurosawa N, Buetow S.

J Health Serv Res Policy. 2015 Oct;20(4):231-9. doi: 10.1177/1355819615593302. Epub 2015 Jul 6.

PMID:
26152909
10.

Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand.

Gauld NJ, Kelly FS, Emmerton LM, Buetow SA.

PLoS One. 2015 Mar 18;10(3):e0119011. doi: 10.1371/journal.pone.0119011. eCollection 2015.

11.

Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison.

Gauld NJ, Kelly FS, Kurosawa N, Bryant LJ, Emmerton LM, Buetow SA.

PLoS One. 2014 Sep 24;9(9):e107726. doi: 10.1371/journal.pone.0107726. eCollection 2014.

12.

Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling.

Gauld NJ, Jennings LC, Frampton C, Huang QS.

J Antimicrob Chemother. 2012 Dec;67(12):2949-56. doi: 10.1093/jac/dks337. Epub 2012 Sep 4.

PMID:
22949624
13.

A new model of prescription to nonprescription reclassification: the calcipotriol case study.

Gauld N, Emmerton L, Kelly F, Buetow S.

Clin Ther. 2012 Jun;34(6):1324-32. doi: 10.1016/j.clinthera.2012.04.019. Epub 2012 May 11.

PMID:
22578311
14.

Is non-prescription oseltamivir availability under strict criteria workable? A qualitative study in New Zealand.

Gauld N, Kelly F, Shaw J.

J Antimicrob Chemother. 2011 Jan;66(1):201-4. doi: 10.1093/jac/dkq409. Epub 2010 Nov 3.

PMID:
21051373

Supplemental Content

Loading ...
Support Center